The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides

Cancer Research

Volumn 62, Issue 11, 2002, Pages 3151-3158

  Motoyama, Andrea B ^a   Hynes, Nancy E ^a   Lane, Heidi A ^a  

^a FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; BETACELLULIN; CGP 59326; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 4D5; NEU DIFFERENTIATION FACTOR; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL DIVISION; DRUG INTERACTIONS; ENZYME INHIBITORS; EPIDERMAL GROWTH FACTOR; G1 PHASE; GROWTH SUBSTANCES; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIGANDS; NEUREGULIN-1; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; PYRROLES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; SUBSTRATE SPECIFICITY; TUMOR CELLS, CULTURED;

EID: 0036606779     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. The ErbB signaling network: Receptor heterodimerization in development and cancer
2. Untangling the ErbB signalling network
3. Neu and its ligands: From an oncogene to neural factors
4. Specificity within the EGF family/ErbB receptor family signaling network
5. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions
6. Distinct characteristics of heregulin signals mediated by HER3 or HER4
7. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling
8. Epidermal growth factor-related peptides and their receptors in human malignancies
9. The EGF receptor family as targets for cancer therapy
10. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
11. Correlation, of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading
12. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer
13. The biology of erbB-2/neu/HER-2 and its role in cancer
14. A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor
15. Development of inhibitors for protein tyrosine kinases
16. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies
17. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor
18. Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo turnout cell growth
19. Growth regulation of human breast and ovarian tumor cells by heregulin: Evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness
20. ErbB2 potentiates breast tumor proliferation through modulation of p27(Kipl)Cdk2 complex formation: Receptor overexpression does not determine growth dependency
21. The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of Herceptin (trastuzumab) therapy for breast cancer
22. Herceptin(R) alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: Pivotal trials
23. Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells
24. 4-(Phenylamino)pyrrolopyrimidines: Potent and selective ATP site direct inhibitor of the EGF-receptor protein tyrosine kinase
25. Tyrosine kinase inhibitors: From rational design to clinical trials
26. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma
27. Mammary glands reconstituted with Neu/ErbB2 transformed HC11 cells provide a novel orthotopic tumor model for testing anti-cancer agents
28. Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells
29. Myc and mammary cancer: Myc is a downstream effector of the ErbB2 receptor tyrosine kinase
30. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies
31. Role of herceptin(R) in primary breast cancer: Views from North America and Europe
32. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells
33. Parsons a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer
34. Heregulin-dependent activation of phosphoinositide 3-kinase and Akt via the ErbB2/ErbB3 co-receptor
35. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin)
36. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets
37. Blocking HER-2/HER-3 function with a dominant negative form of HER-3 in cells stimulated by heregulin and in breast cancer cells with HER-2 gene amplification
38. Formation of a high affinity heregulin binding site using the soluble extracellular domains of ErbB2 with ErbB3 or ErbB4
39. Dynamic expression and activation of ERBB receptors in the developing mouse mammary gland
40. ErbB4 signaling in the mammary gland is required for lobuloalveolar development and Stat5 activation during lactation
41. Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells
42. Type 1 receptor tyrosine kinases are differentially phosphorylated in mammary carcinoma and differentially associated with steroid receptors
43. c-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer
44. Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225
45. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: Potential therapy for cancer